Centonze, Diego
Rocca, Maria A.
Gasperini, Claudio
Kappos, Ludwig
Hartung, Hans-Peter
Magyari, Melinda
Oreja-Guevara, Celia
Trojano, Maria
Wiendl, Heinz
Filippi, Massimo http://orcid.org/0000-0002-5485-0479
Article History
Received: 17 February 2021
Revised: 1 April 2021
Accepted: 3 April 2021
First Online: 12 April 2021
Declarations
:
: D. Centonze is an Advisory Board member of Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva and received honoraria for speaking or consultation fees from Almirall, Bayer Schering, Biogen, GW Pharmaceuticals, Merck Serono, Novartis, Roche, Sanofi-Genzyme, and Teva. He is also the principal investigator in clinical trials for Bayer Schering, Biogen, Merck Serono, Mitsubishi, Novartis, Roche, Sanofi-Genzyme, and Teva. His preclinical and clinical research was supported by grants from Bayer Schering, Biogen Idec, Celgene, Merck Serono, Novartis, Roche, Sanofi-Genzyme and Teva. M.A. Rocca received speakers honoraria from Bayer, Biogen, Bristol Myers Squibb, Celgene, Genzyme, Merck Serono, Novartis, Roche, and Teva, and receives research support from the Italian Ministry of Health, MS Society of Canada and Fondazione Italiana Sclerosi Multipla. C. Gasperini has received funding for an invited speaker or travel expenses for attending meetings from Biogen, Genzyme, Merck Serono, Novartis, Roche, Sanofi, and Teva. L. Kappos ́institution (University Hospital Basel) has received in the last 3 years and used exclusively for research support: steering committee, advisory board, and consultancy fees (Actelion, Bayer Health-Care, Biogen, Genzyme, Merck KGaA [Darmstadt, Ger-many], Novartis, Pfizer, Sanofi, Santhera, Teva); speaker fees (Bayer HealthCare, Biogen, Merck KGaA [Darmstadt, Germany], Novartis, Sanofi, and Teva); support of educational activities (Bayer HealthCare, Biogen, CSL Behring, Genzyme, Merck KGaA [Darmstadt, Germany], Novartis, Sanofi, and Teva); license fees for Neurostatus products; and grants (Bayer HealthCare, Biogen, European Union, Innoswiss, Merck KGaA [Darmstadt, Germany], Novartis, Roche, Swiss MS Society, and Swiss National Research Foundation). H.-P. Hartung has received fees for consulting, speaking, and serving on steering committees from Bayer HealthCare, Biogen Idec, Celgene BMS, CSL Behring, GeNeuro, Genzyme, MedDay, MedImmune, Merck Serono, Novartis, Roche, Sanofi, TG Therapeutics, and VielaBio with approval by the Rector of Heinrich Heine University Düsseldorf. M. Magyari has served on scientific advisory board for Biogen, Sanofi, Roche, Novartis, Merck, Abbvie, Alexion, has received honoraria for lecturing from Biogen, Merck, Novartis, Sanofi, has received research support and support for congress participation from Biogen, Genzyme, Roche, Merck, Novartis. C. Oreja-Guevara has received speaker and consultation fees from Biogen Idec, Celgene, Sanofi-Genzyme, Novartis, Roche, Merck, and Teva. M. Trojano received speaker’s honoraria, consulting fees, honoraria in advisory boards, support for attendance of scientific meetings from Meck Serono, Biogen, Novartis, Teva, Roche and Sanofi Genzyme. H. Wiendl received speaker’s honoraria, consulting fees, honoraria in advisory boards, support for attendance of scientific meetings from Actelion, Alexion, Biogen, Cognomed, Evgen, F. Hoffmann-La Roche Ltd., GemeinnützigeHertie-Stiftung, Genzyme,IGES, Johnson & Johnson,MedDay Pharmaceuticals, Merck Serono, Novartis, Roche Pharma AG, and Sanofi-Aventis, the Swiss Multiple Sclerosis Society. TEVA, and WebMD Global. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Else Kröner Fresenius Foundation, Fresenius Foundation, the European Union, Hertie Foundation, NRW Ministry of Education and Research, Interdisciplinary Center for Clinical Studies (IZKF) Muenster, Biogen, GlaxoSmithKline, Roche Pharma, andSanofi-Genzyme. M. Filippi is Editor-in-Chief of the <i>Journal of Neurology</i> and Associate Editor of <i>Human Brain Mapping</i>; received compensation for consulting services and/or speaking activities from Almiral, Alexion, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione ItalianaSclerosiMultipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).
: Not applicable.